Results 211 to 220 of about 20,192 (256)
Some of the next articles are maybe not open access.
Journal of glaucoma, 2018
Purpose: To investigate, using in vivo confocal microscopy (IVCM), the Meibomian gland (MG) features and conjunctival goblet cell density (GCD) in glaucomatous patients controlled with prostaglandin/timolol fixed combinations (PTFCs).
L. Agnifili +6 more
semanticscholar +1 more source
Purpose: To investigate, using in vivo confocal microscopy (IVCM), the Meibomian gland (MG) features and conjunctival goblet cell density (GCD) in glaucomatous patients controlled with prostaglandin/timolol fixed combinations (PTFCs).
L. Agnifili +6 more
semanticscholar +1 more source
Timolol and Pediatric Glaucomas
Ophthalmology, 1981Thirty-eight eyes were treated by adding timolol to the medical regimen. After a suitable trial, attempts were made to reduce other glaucoma medications. Fifteen eyes with infantile glaucoma treated surgically at birth, experienced elevated intraocular pressure later in life.
Robert N. Shaffer +3 more
openaire +3 more sources
Survey of Ophthalmology, 1979
Of 145 patients registered for an investigation of timolol, 27 patients were dropped for unrelated reasons. Among the remaining 118 patients (212 eyes), a significant reduction in intraocular pressure resulted from twice-a-day topical instillation of 0.25 or 0.5% timolol to ocular hypertensives, primary open-angle glaucoma or aphakic glaucoma patients.
Luke-Long Lin +7 more
openaire +3 more sources
Of 145 patients registered for an investigation of timolol, 27 patients were dropped for unrelated reasons. Among the remaining 118 patients (212 eyes), a significant reduction in intraocular pressure resulted from twice-a-day topical instillation of 0.25 or 0.5% timolol to ocular hypertensives, primary open-angle glaucoma or aphakic glaucoma patients.
Luke-Long Lin +7 more
openaire +3 more sources
Safety and efficacy of topical timolol treatment of infantile haemangioma: a prospective trial
British Journal of Dermatology, 2018DEAR EDITOR, Topical timolol therapy is considered a relatively ‘safer’ alternative for the treatment of infantile haemangiomas (IH); however, sufficient supportive pharmacokinetic data does not exist.
Jenna Borok +6 more
semanticscholar +1 more source
Survey of Ophthalmology, 1983
Timolol maleate, a nonselective beta blocker, has been associated with adverse reactions when administered topically or systemically. The current literature pertaining to timolol-related side effects and reports to the National Registry of Drug Induced Ocular Side Effects are reviewed.
Thom J. Zimmerman +2 more
openaire +3 more sources
Timolol maleate, a nonselective beta blocker, has been associated with adverse reactions when administered topically or systemically. The current literature pertaining to timolol-related side effects and reports to the National Registry of Drug Induced Ocular Side Effects are reviewed.
Thom J. Zimmerman +2 more
openaire +3 more sources
Survey of Ophthalmology, 1983
In determining the role of timolol in the treatment of childhood glaucoma, the difficulties of conducting investigational studies in children and the possible delayed appearance of longterm side effects are real concerns. However, an equally important consideration is the fact that young children may face a lifetime of blindness from uncontrolled ...
William P. Boger, William P. Boger
openaire +2 more sources
In determining the role of timolol in the treatment of childhood glaucoma, the difficulties of conducting investigational studies in children and the possible delayed appearance of longterm side effects are real concerns. However, an equally important consideration is the fact that young children may face a lifetime of blindness from uncontrolled ...
William P. Boger, William P. Boger
openaire +2 more sources
Ophthalmology, 1979
Data from clinical records of patients using timolol confirm the ocular hypotensive effect of the drug in secondary glaucoma, aphakic glaucoma, ocular hypertension, and when used in combination with various other forms of glaucoma therapy. No serious local or systemic side effects were noted.
Thom J. Zimmerman, Pamela Canale
openaire +3 more sources
Data from clinical records of patients using timolol confirm the ocular hypotensive effect of the drug in secondary glaucoma, aphakic glaucoma, ocular hypertension, and when used in combination with various other forms of glaucoma therapy. No serious local or systemic side effects were noted.
Thom J. Zimmerman, Pamela Canale
openaire +3 more sources
AAPS PharmSciTech, 2017
This study was conducted to develop timolol maleate (TM)-loaded galactosylated chitosan (GC) nanoparticles (NPs) (TM-GC-NPs) followed by optimization via a four-level and three-factor Box–Behnken statistical experimental design.
Ruobing Zhao +5 more
semanticscholar +1 more source
This study was conducted to develop timolol maleate (TM)-loaded galactosylated chitosan (GC) nanoparticles (NPs) (TM-GC-NPs) followed by optimization via a four-level and three-factor Box–Behnken statistical experimental design.
Ruobing Zhao +5 more
semanticscholar +1 more source
GLAUCOMA TREATMENT WITH TIMOLOL
Acta Ophthalmologica, 1978Thirty‐two eyes from 19 patients with either capsular glaucoma, pigmentary glaucoma or primary open angle glaucoma were given topical timolol and followed through a 3–6 months period.Twelve eyes were previously out of control on full medication including pilocarpine, epinephrine and acetazolamide.
Emilia Kerty, Ivar Hørven
openaire +3 more sources
Frequency of Timolol Administration
American Journal of Ophthalmology, 1981We treated 20 patients who had primary open-angle glaucoma with either 0.25% or 0.5% timolol for nine weeks. Once-daily administration of timolol significantly reduced intraocular pressure (to less than 21 mm Hg) in nine patients; four patients required twice-daily administration. In seven cases, we judged the treatment to have failed.
Leonard Rothkoff +4 more
openaire +3 more sources